Orasis Pharmaceuticals

Company Overview

Snapshot

Founded in September 2015, Orasis Pharmaceuticals operates with 51–200 employees. The company has raised $121M across 5 funding rounds from 12 investors. In October 2024, Orasis Pharmaceuticals completed a $78M financing round to support the commercial launch of its FDA-approved eye drop, QLOSI.

Business overview

Orasis Pharmaceuticals is an ophthalmic pharmaceutical company focused on developing corrective eye drops for presbyopia, a condition characterized by the gradual loss of the eye's ability to focus on near objects. Its core product, QLOSI™ (pilocarpine HCl ophthalmic solution) 0.4%, is an FDA-approved prescription eye drop designed to offer an alternative to reading glasses. The company serves the ophthalmology market within the broader health tech and life sciences sector, targeting individuals affected by presbyopia.

Strategic signal

In October 2024, Orasis Pharmaceuticals secured a $78 million financing round, a significant capital injection aimed at supporting the commercial launch of its FDA-approved QLOSI eye drops. This funding signals strong investor confidence in the company's ability to bring its presbyopia treatment to market and establish a commercial footprint, indicating a critical transition from development to market entry for a novel ophthalmic solution.

Company Intelligence Q&A

What was the most recent funding event for Orasis Pharmaceuticals?

In October 2024, Orasis Pharmaceuticals completed a $78M financing round. This funding was led by Arboretum Ventures and joined by Visionary Ventures, among others, to support the commercial launch of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4%.

When did Orasis Pharmaceuticals receive FDA approval for its lead product?

Orasis Pharmaceuticals announced the FDA approval of QLOSI™ (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in October 2023.

Has Orasis Pharmaceuticals entered into any recent commercialization agreements?

In October 2024, Orasis Pharmaceuticals announced a licensing agreement with Optus Pharmaceuticals for the commercialization of QLOSI eye drops in Korea, expanding its market reach internationally.

When did Orasis Pharmaceuticals submit its New Drug Application (NDA) for CSF-1?

Orasis Pharmaceuticals submitted a New Drug Application for its investigational novel eye drop candidate, CSF-1, for the treatment of presbyopia in January 2023. The FDA accepted this application in February 2023.

When did Orasis Pharmaceuticals raise its Series C funding?

In September 2020, Orasis Pharmaceuticals raised a Series C round to advance the clinical development of its novel treatment for presbyopia. This round was led by Bluestem Capital and joined by Maverick Ventures Israel.